experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p<0.001) and had a high rate of MGMT promoter unmethylated tumors.Conclusions:Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Never...
GlioblastomaMismatch repairCMMRDLynchIDHATRXDNA methylationSubtypePrognosisDiffuse IDH-mutant astrocytoma mostly occurs in adults and carries a favorable prognosis compared to IDH-wildtype malignant gliomas. Acquired mismatch repair deficiency is known to occur in recurrent IDH-mutant gliomas as resistance ...
While some biologic differences between IDH mutated (IDH mut) and wild-type (IDH wt) gliomas are clear, the distinct alterations associated with progression of the two subtypes to glioblastoma (GBM, Grade IV) have not been well described. We analyzed copy number alterations (CNAs) across grades...
In order to evaluate NF1 protein expression, we created a tissue microarray (TMA) from 69 representative glioblastomas from the cohort described above. Forty-four samples wereNF1-wildtype and 25 wereNF1-mutant on next-generation sequencing. All but one was obtained from the first tumor resection...
Conclusion: Radiation therapy, along with temozolomide, is still the standard of care for most people with MGMT-unmethylated GBMs because there aren't any better options, and it's generally safe and well-tolerated. These patients have a lower overall survival rate and less benef...
-mutant patients with GBM,independently of age,gender distribution,tumor type(primary or recurrent/secondary),and the extent of resection.Conclusions:MGMT promoter methylation has predictive value in IDH-mutant glioblastoma,but its cutoff value should be higher than that for IDH-wildtype glioblastoma....
glioblastomaIDH‐wildtypeMGMTsurvivalObjective Accumulating evidence from recent molecular diagnostic studies has indicated the prognostic significance of various genetic markers for patients with glioblastoma (GBM). To evaluate the impact of such genetic markers on prognosis, we retrospectively analyzed the ...
methylation status, except MGMT promoter-unmethylated AIAN experienced 70% higher risk of death than NHW (aHR=1.70, p=0.021).Conclusions:Our findings suggests that racial/ethnic disparities exist in healthcare utilization, postoperative outcomes, and overall survival inIDH-wildtype glioblastoma ...
MGMT promoter methylation status is the most predictive and prognostic molecular biomarker and roughly 40% of IDH-wildtype glioblastomas will be methylated [95]. From a modern pooled analysis of 5 phase III trials, the median OS in MGMT methylated patients is approximately 24 months compared to...
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas Article Open access 14 May 2019 Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients Article Open access 05 June 2019 DICER1 mutations in primary central nervous system tumors: new...